AgomAb Therapeutics (NASDAQ:AGMB) Director David Epstein Purchases 5,000 Shares of Stock

AgomAb Therapeutics NV (NASDAQ:AGMB – Get Free Report) Director David Epstein bought 5,000 shares of AgomAb Therapeutics stock in a transaction on Thursday, October 8th. The shares were bought at an average cost of $8.90 per share, with a total value of $44,500.00. Following the acquisition, the director directly owned 15,000 shares in the company, valued at approximately $133,500. This represents a 50.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

AgomAb Therapeutics Price Performance

Shares of AgomAb Therapeutics stock opened at $9.08 on Friday. AgomAb Therapeutics NV has a 12-month low of $7.97 and a 12-month high of $17.82. The company’s 50-day moving average price is $12.60 and its 200-day moving average price is $11.93.

Get AgomAb Therapeutics alerts:

AgomAb Therapeutics (NASDAQ:AGMB – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. Equities analysts forecast that AgomAb Therapeutics NV will post -1.76 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. HC Wainwright restated a “buy” rating on shares of AgomAb Therapeutics in a research report on Wednesday, September 16th. Cantor Fitzgerald initiated coverage on AgomAb Therapeutics in a research note on Wednesday, August 19th. They set an “overweight” rating for the company. Piper Sandler started coverage on AgomAb Therapeutics in a research report on Tuesday, August 25th. They set an “overweight” rating and a $60.00 target price for the company. Wall Street Zen lowered AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, September 27th. Finally, B. Riley Financial initiated coverage on AgomAb Therapeutics in a research report on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target for the company. Seven analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $37.50.

Check Out Our Latest Stock Report on AGMB

AgomAb Therapeutics Company Profile

(Get Free Report)

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab’s lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn’s disease.

Further Reading

• Five stocks we like better than AgomAb Therapeutics
• Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
• Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
• Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
• Arista Networks Plugs Into All-Time Highs

Receive News & Ratings for AgomAb Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgomAb Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.